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ABSTRACT
Background: Cardiovascular disease is a major
cause of morbidity and mortality; however, the
risks associated with this disease can be reduced
by targeting circulating low-density lipoprotein
cholesterol (LDL-C) with lipid-lowering drugs,
as recommended in many treatment guidelines.
Their effectiveness for hypercholesterolemia
management depends on appropriate use in
at-risk patients. Observational studies have
shown varying adherence to national and
international guidelines on reaching LDL-C
treatment goals.
Methods: The Centralized Pan-Middle East
Survey on the under-treatment of
hypercholesterolemia (CEPHEUS) study
observed the current management of
hypercholesterolemia in patients on lipid-
lowering drugs in seven Middle Eastern
countries, and results from 1,043 patients in
Egypt are presented here.
Results: Overall, less than 50% of patients
achieved their LDL-C treatment goal, with
patients at higher risk of a cardiovascular
event being less likely to attain their target.
Nearly, three-quarters of patients in this study
were considered high or very high risk, with
only 10% of high-risk patients reaching their
treatment goal.
Conclusions: Management of
hypercholesterolemia in Egypt is
comparatively worse than the average for
similar countries in the region, and many
patients with high risk of CVD are not being
effectively treated. Initiatives to improve
Trial registration: ClinicalTrials.gov Identifier:
NCT01604733, NIS-EG-CRE-2012/01.
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physicians’ management of these patients and
patient compliance to treatment are urgently
needed.
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INTRODUCTION
Cardiovascular disease (CVD) is the most
common cause of death worldwide,
accounting for an estimated 17.3 million
deaths in 2008 and representing 30% of all
global deaths [1]. The World Health
Organization projects that CVD will remain
the leading cause of death worldwide in future
years, with deaths from CVD estimated to
increase to 23.3 million by 2030 [1, 2].
Currently, over 80% of CVD deaths occur in
low- and middle-income countries [1]. This has
been attributed to the fact that people in these
countries are typically exposed to more risk
factors, such as tobacco and dyslipidemia [high
apolipoprotein B (ApoB):apolipoprotein A1
(ApoA1) ratio] [3]. In addition, they are likely
to have less access to early detection and
prevention programs than patients in more
developed countries [3]. These factors also
contribute to the fact that the mean age
[±standard deviation (SD)] of first presentation
of acute myocardial infarction (AMI) has been
observed to be 51.2 (±10.3) years in Middle
Eastern countries, approximately 10 years
younger than in other regions of the world [3,
4]. Furthermore, the Middle East has the highest
proportion of first AMI in individuals aged
40 years or younger [4].
In Egypt, the age-standardized annual death
rate from CVD is over 400 per 100,000
population, and this compares to rates of less
than 150 per 100,000 population in some
European countries [5]. The Egyptian National
Hypertension Project, which surveyed over
6,700 subjects, reported the national incidence
of coronary heart disease to be 8.3% [5]. The
incidence was higher in women than men
(8.9% versus 8.0%, respectively) and higher in
urban populations than rural populations (8.8%
versus 7.2%, respectively).
There is epidemiological evidence that
elevated total serum cholesterol, specifically
elevated levels of low-density lipoprotein
cholesterol (LDL-C), is strongly correlated with
the risk of coronary heart disease [6–10]. Thus, a
principal intervention to reduce the risk of
cardiovascular events in patients with CVD is
to control the level of circulating lipids,
particularly LDL-C [8, 11, 12]. Clinical
intervention studies have shown that the
impact of lipid-lowering treatment is primarily
dependent on the individual’s baseline risk of a
cardiovascular event, and that the reduction in
risk of an event subsequently occurring is
proportional to the degree of LDL-C lowering
achieved by treatment [8, 11–13]. Therefore,
since the late 1980s, guidelines for the
prevention of CVD have recommended
treatment goals based on reducing the baseline
risk of the patient. The US National Cholesterol
Education Program Adult Treatment Panel III
guidelines (NCEP ATP III) on cholesterol
management, originally produced in 2002
[10], were updated in 2004 [14] to reflect the
findings of major clinical trials that confirmed
the benefits of lipid-lowering therapy in high-
risk, diabetic and elderly patients.
With the introduction of more stringent
guidelines and the widespread increased use of
lipid-lowering therapy, there is a need to
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evaluate the current level of under-treatment of
hypercholesterolemia. It is also important to
understand why patients being actively treated
with lipid-lowering drugs do not achieve their
treatment goal. The Centralized Pan-Middle
East survey on the under-treatment of
hypercholesterolemia (CEPHEUS) assessed the
current management of hypercholesterolemia
in patients on lipid-lowering drugs in Middle
Eastern countries [Bahrain, Egypt, Oman, Qatar,
the United Arab Emirates (UAE), the Kingdom
of Saudi Arabia (KSA) and Kuwait]. The primary
aim of this study was to establish the proportion
of patients on lipid-lowering pharmacological
treatment who attained their LDL-C treatment
goal, as defined by NCEP ATP III 2002 and 2004
guidelines. Secondary endpoints included:
evaluation of the proportion of patients in
pre-defined sub-populations achieving their
LDL-C treatment goal, identification of
determinants (patient and physician
characteristics) for patients not reaching their
treatment goal and physician characteristics
associated with the allocation of different
treatment regimens. The results reported here
are for the Egyptian arm of this study, which
was conducted in Cairo and Alexandria.
METHODS
Study Design
This was a multicenter, observational study of
patients receiving lipid-lowering
pharmacological treatment in Cairo and
Alexandria, Egypt, conducted in 2010 and
2011 as part of the CEPHEUS study
(clinicaltrials.gov identifiers: NCT01604733,
NIS-EG-CRE-2012/01). All procedures followed
were in accordance with the ethical standards of
the responsible committee on human
experimentation (institutional and national)
and with the Helsinki Declaration of 1975, as
revised in 2000 and 2008, and are consistent
with the International Conference on
Harmonisation/Good Clinical Practice (ICH-
GCP). Informed consent was obtained from all
patients for being included in the study.
Study Objectives
The primary objective of the study was to
establish the proportion of patients receiving
lipid-lowering pharmacological treatment who
reach their LDL-C goals, according to the NCEP
ATP III/NCEP ATP III 2004 updated guidelines
[10, 14]. These guidelines recommend a
therapeutic LDL-C goal of\100 mg/dL for
those at high risk of cardiovascular events (10-
year risk[20% of coronary heart disease), with
an option to further lower the goal to\70 mg/
dL for individuals at very high risk (established
coronary heart disease and multiple major risk
factors, severe and persistent risk factors,
metabolic syndrome or acute coronary
syndrome). The recommended LDL-C goal for
those at moderately high risk (two or more risk
factors and a 10-year risk of 10–20%)
is\130 mg/dL [14]. For patients considered at
low risk, non-pharmacological intervention
such as changes in diet, smoking cessation and
an increase in exercise are generally
recommended. For patients at a higher risk,
lipid-lowering drugs, e.g., statins, fibrates or
cholesterol absorption inhibitors, are
recommended.
Key secondary objectives were to establish
the proportion of patients achieving their
treatment goals and the proportion of patients
achieving their target goals in the following
sub-populations: primary/secondary prevention
patients and patients with metabolic syndrome
(defined according to NCEP ATP III). Other
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secondary goals were: to establish the
proportion of patients on lipid-lowering
pharmacological treatment reaching the non-
high-density lipoprotein cholesterol (HDL-C)
goals according to the NCEP ATP III/NCEP
ATP III 2004 updated guidelines (\130 mg/dL)
in the sub-population of patients with fasting
triglycerides[200 mg/dL; to identify
determinants (e.g., patient and physician
characteristics, country-specific guidelines or
recommendations) for under-treatment of
hypercholesterolemia; and to explore
physician characteristics associated with the
allocation of different treatment regimens.
NCEP ATP III 2004 updated guidelines and
goals were used to evaluate management
efficacy because they were the most
commonly used at the time of study.
Study Inclusion Criteria
Subjects fulfilling the following inclusion
criteria were enrolled in the study:
age C18 years; receiving lipid-lowering drug
treatment for at least 3 months with no dose
change for at least 6 weeks; and provision of
written informed consent to participate in the
study and comply with study procedures.
Study Procedures
The study planned to enroll 1,100 randomly
selected patients being treated by 78 specialists
and primary care physicians located in Cairo
and Alexandria, Egypt. The required sample
size was calculated to ensure that the primary
and secondary endpoints could be estimated
with sufficient precision to represent the
heterogeneity of this population, and was
based on an estimated 50% of participants
being expected to achieve their treatment
goal.
Prior to assessing their first study participant,
each investigator was required to complete a
questionnaire on their experience and
perception of the management of
hypercholesterolemia observed in their
patients. Consecutive patients who came for a
regularly scheduled visit to the clinic were
invited to participate in the survey. Each study
participant was required to attend a single clinic
visit, during which a fasting blood sample was
obtained for analysis of total cholesterol, LDL-
C, HDL-C, triglycerides, glucose, glycosylated
hemoglobin (HbA1c) and calculation of the
ratio of total cholesterol/HDL cholesterol.
Three separate samples were collected from
each patient and all samples were analyzed at
the accredited central laboratory in Cairo.
Participants also underwent a physical
examination by the investigator to determine
their height, weight, waist circumference and
blood pressure. Following the visit, investigators
received the laboratory results together with a
copy of the NCEP ATP III 2004 updated
guidelines [14]. These were supplied to the
investigators for educational purposes to
enable them to take any appropriate measures
regarding the future treatment of the patient.
Prior to attendance at the clinic, participants
were required to complete a questionnaire
relating to their awareness of
hypercholesterolemia, their current treatment
schedule, treatment goals, satisfaction with
treatment and their compliance to treatment.
Investigators also completed a patient record
form for each participant, detailing the patient’s
demographics, known cardiovascular risk
factors, cardiovascular medical history, current
lipid-lowering drug treatment and rationale for
their current treatment. Each subject had their
risk category according to NCEP ATP III 2004
updated guidelines determined
programmatically by an expert panel.
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Statistical Analysis
The statistical analysis was of a descriptive
nature. Continuous data are described by
mean, SD, median, minimum and maximum
values. Categorical data are described by the
number and percentage of subjects in each
category. Missing data were not included in
the calculation of proportions. The association
between achievement of LDL-C goals and
patient/physician variables was analyzed by a
multivariate logistic regression model.
Table 1 Patient demographics and clinical characteristics
Variable Value
Age, years, mean (SD) 57.73 (11.20)
Male, n (%) 525 (50.30)
Female, n (%) 518 (49.70)
Blood pressure, mm Hg (SD)
Mean systolic 135.55 (17.28)
Mean diastolic 84.82 (9.96)
Body weight, kg, mean (range) 89.2 (48.00–170.00)
Waist circumference, cm, mean (range) 105.39 (60.00–180.00)
Body mass index, kg/m2, mean (range) 31.83 (17.10–69.20)
History of coronary heart disease, n (%) 431 (41.30)
History of cerebrovascular disease, n (%) 117 (11.20)
History of peripheral arterial disease, n (%) 75 (7.20)
Family history of premature cardiovascular disease, n (%) 373 (35.80)
Comorbidities, n (%)
Diabetes 506 (48.50)
Arterial hypertension 739 (70.80)
Current smoker, n (%) 197 (18.90)
Reason for pharmacological therapy, n (%)
Primary prevention 630 (60.40)
Secondary prevention 374 (35.70)
Familial hypercholesterolemia 39 (3.70)
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RESULTS
A total of 1,182 patients were enrolled in this
study between 13 October 2010 and 7 June
2011. One hundred and thirty-nine patients
were excluded from the analysis due to missing
LDL-C data, resulting in data from 1,043
patients being included in the final analysis.
The demographics and clinical characteristics of
the study cohort are reported in Table 1. The
mean age of participants was 54.73 years, and
50.30% were male. The main reason for
pharmacological treatment was primary
prevention (60.40%), and statins were the
most frequent treatment of choice (94.20%).
The mean laboratory blood values for all
variables analyzed in the study are given in
Table 2.
Overall, 32.5% of patients achieved their
LDL-C treatment goal according to criteria
outlined in the NCEP ATP III 2004 updated
guidelines (Table 3). Patients considered to have
a low or medium–low risk profile (as determined
by NCEP ATP III 2004 updated guidelines
criteria) had the highest rate of achieving their
LDL-C treatment goal (Fig. 1; Table 3). Out of
187 subjects with fasting triglycerides[200 mg/
dL ([2.26 mmol/L), 103 patients (55.10%)
achieved their non-HDL-C treatment goal; it
should be noted that information on other
drugs that could have affected non-HDL-C
levels is not available.
In patients with arterial hypertension, a
family history of CVD or metabolic syndrome,
26.0, 30.0 and 26.1%, respectively, attained
their LDL-C treatment goals, as defined by the
NCEP ATP III 2004 updated guidelines (Table 4).
The proportion of current smokers and patients
with diabetes achieving their treatment goals
was low at 17.3% and 20.6%, respectively.
Using the NCEP ATP III 2004 updated
guidelines treatment goal criteria, the most
effective statins were rosuvastatin, pravastatin
and simvastatin, with 39.0, 37.5 and 33.8% of
patients prescribed these medications achieving
their LDL-C treatment goals, respectively
(Table 3).
Results of the Investigators’ Questionnaire
Seventy-seven of the 78 participating
investigators, covering a total of 122 sites,
returned a completed questionnaire. Most of
the investigators were male (92.2%) with a
mean age of 50.5 years (SD 7.3). The majority
of the investigators were cardiologists (55.8%);
10.4% were endocrinologists, 29.9% were other
specialists and 3.9% were primary care
physicians.
Most investigators (76.0%) stated that they
used guidelines to establish the individual
target cholesterol levels of patients, with over
half of these using the NCEP ATP III 2004
updated guidelines. Additional data from the
investigators’ questionnaire is presented in
Table 5.





194.45 (5.03) 48.16 (1.25)
LDL-C, mg/dL (mmol/L) 119.28 (3.08) 40.87 (1.06)
HDL-C, mg/dL (mmol/L) 45.70 (1.18) 12.06 (0.31)
Triglycerides, mg/dL
(mmol/L)
147.04 (1.66) 105.06 (1.19)
HbA1c, % (mmoL/moL) 7.42 (58.00) 1.99 (-2.00)
Glucose, mg/l 128.31 58.31
HbA1c glycosylated hemoglobin, HDL-C high-density
lipoprotein cholesterol, LDL-C low-density lipoprotein
cholesterol, SD standard deviation
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Results of the Patient Questionnaire
All of the 1,043 patients available for analysis
returned the questionnaire with at least one
question completed. Most patients had heard
about, or been told about, LDL-C and HDL-C
(78.0% and 70.7%, respectively). The majority
(80.6%) had been informed of their cholesterol
levels by their physician, and 76.0% had been
given a target cholesterol level. Additional
responses to the patients’ questionnaire are
shown in Table 6.
Multivariate Analysis of Factors Associated
with Achieving LDL-C Treatment Goal
The main patient and physician factors that
were significantly associated with patients
Table 3 Patient baseline risk category according to the NCEP ATP III 2004 updated guidelines; the number of patients in
each risk category obtaining their treatment goals, overall and according to statin prescribed
Patient characteristics Risk
category










to prescribed statin, n (%)
[mean dose, mg – SD]








Established CVD plus diabetes,
smoker, low HDL-C and high
triglycerides, metabolic syndrome






393 (37.7) 42 (10.7) Rosuvastatin: 14 (11.4)
[NA]
Atorvastatin: 21 (10.4) [NA]
Simvastatin: 4 (8.9) [NA]




362 (34.7) 124 (34.2) Rosuvastatin: 46 (49.0)
[NA]
Atorvastatin: 53 (40.0) [NA]
Simvastatin: 20 (45.6) [NA]
[2 risk factors with Framingham





38 (3.6) 3 (7.9) Rosuvastatin: 1 (9.1) [NA]
Atorvastatin: 1 (6.2) [NA]
Simvastatin: 1 (20.0) [NA]






167 (16.0) 111 (66.5) Rosuvastatin: 47 (78.2)
[NA]
Atorvastatin: 42 (65.6) [NA]
Simvastatin: 14 (51.8) [NA]
0–1 risk factor Low \160 mg/dL
(4.14 mmol/L)
83 (8.0) 59 (71.1) Rosuvastatin: 27 (79.4)
[NA]
Atorvastatin: 18 (64.3) [NA]
Simvastatin: 7 (58.3) [NA]
CHD coronary heart disease, CVD cardiovascular disease, DBP diastolic blood pressure, HDL-C high-density lipoprotein
cholesterol, LDL-C low-density lipoprotein cholesterol, NCEP ATP III National Cholesterol Education Program Adult
Treatment Panel III, NA not available, SBP systolic blood pressure, SD standard deviation
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not attaining their NCEP ATP III 2004
updated LDL-C treatment goal were:
forgetting to take tablets [odds ratio (OR)
3.3; 95% confidence interval (CI) 1.2–8.6];
being diabetic (OR 2.7; CI 2.0–3.6); smoking
(OR 2.4; CI 1.6–3.9); and age\40 years (OR
1.8; CI 0.9–3.6).
DISCUSSION
The primary aim of this study was to investigate
the proportion of patients receiving lipid-
lowering pharmacological treatment in Egypt
who reach their LDL-C treatment goals. Study
subjects had already been receiving lipid-
lowering medications prior to their inclusion.
Overall, this study found that the management
of patients requiring lipid-lowering therapeutic
intervention is moderate to poor in Egypt, with
less than 50% of treated patients achieving the
treatment goals stipulated in the NCEP ATP III
2004 updated guidelines. When looking at the
success of treatment in patients categorized
according to risk, those considered very high
risk (who comprised 38% of the study
population) were particularly poorly managed,
with only 10% achieving their treatment goal.
In contrast, over 65% of patients in the low or
medium–low risk categories successfully
attained their treatment goal, although it
should be noted that these combined patient
Fig. 1 Patient baseline risk category according to the NCEP ATP III 2004 updated guidelines obtaining their treatment
goals. NCEP ATP III US National Cholesterol Education Program Adult Treatment Panel III guidelines
Table 4 Patients achieving LDL-C treatment goals,
deﬁned by the NCEP ATP III 2004 updated guideline
criteria, depending on risk factors
Variable Patients achieving
treatment goal, n (%)
Patients achieving LDL treatment goal with risk factors
Metabolic syndrome 132 (26.1)
Current smoker 34 (17.3)
Diabetes 104 (20.6)
Arterial hypertension 192 (26.0)
CVD family history 112 (30.0)
CVD cardiovascular disease, LDL-C low-density
lipoprotein cholesterol, NCEP ATP III National
Cholesterol Education Program Adult Treatment Panel III
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groups only accounted for a quarter of the study
population; most study participants were in the
very high and high-risk categories (72.4%).
These findings conflict with the result that
most investigators (74%) stated that they used
guidelines to establish individual target
cholesterol levels for patients, most commonly
the NCEP ATP III 2004 updated guidelines. The
findings are also in contrast to the beliefs of the
treating physicians, as more than 60% of
investigators either agreed or strongly agreed
with the statement that they felt a sufficient
number of patients reached their target levels.
However, the finding is more in line with
patient perception, as only around 50% of
patients stated that they were satisfied with
their treatment.
Evaluation of sub-groups of patients with
established risk factors for CVD showed that
hypercholesterolemia was particularly poorly
managed in patients who were current
smokers (18.9% of participants) or were
diabetic (48.5% of participants), whereas only
17.3% and 20.6% of patients, respectively,
attained their NCEP ATP III 2004 updated
LDL-C treatment goal. Patients with metabolic
syndrome, arterial hypertension or a family
history of CVD, 30% or less were successfully
treated.
The majority of patients in this study
(85.9%) were prescribed statins, which are well
established as an effective treatment of
dyslipidemia [15, 16]. The most commonly
prescribed statins were atorvastatin and
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rosuvastatin, prescribed for 48.9% and 34.9%,
respectively, of those patients receiving statins.
The most effective statins according to this
study were rosuvastatin, pravastatin and
simvastatin, with 39.0, 37.5 and 33.8% of
patients who were prescribed these
medications achieving their LDL-C treatment
goals, respectively. It should be remembered
that the number of patients in the lower risk
categories was low, and some of the most
favorable results were observed in patients
categorized according to the NCEP ATP III
2004 updated guidelines as medium or low
risk who were treated with rosuvastatin. In
these sub-groups of patients,[70% of patients
were successfully treated.
Results of the patient questionnaire reported
that most patients ([80%) had not changed
their medication from their initial treatment
recommendation at diagnosis, and less than
10% had received a dose increase. This finding
could suggest that failure of treating physicians
to adapt an individual’s response to treatment
may be a factor in the overall failure of patients
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Table 7 Overall proportion of patients achieving LDL-C
target levels in CEPHEUS studies
Country/region Overall proportion
achieving LDL-C target, %
Egypt (this study) 32.5
Middle East [17] 52.0
Western Europe [20] 57.4
Greece [19] 49.3
South Africa [18] 60.5
Asia [21] 49.1
Hong Kong [22] 82.9
CEPHEUS Centralized Pan-Middle East Survey on the
under-treatment of hypercholesterolemia, LCL-C low-
density lipoprotein cholesterol
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to be successfully managed for
hypercholesterolemia.
Patient compliance to treatment is another
factor that could influence treatment outcomes.
In this study, 12% of patients admitted
forgetting to take their prescribed medication
more than once a week, and 16% stated that
they forgot no more than once a month.
Furthermore, in the multivariate analysis,
forgetting to take tablets was strongly
correlated with not attaining treatment goals.
A report of the CEPHEUS study in six Middle
Eastern countries (Bahrain, Oman, Qatar, UAE,
KSA and Kuwait), concluded that
hypercholesterolemia was sub-optimally
managed across these countries, particularly in
those with a high or very high risk of a
cardiovascular event [17]. In the overall
regional analysis, 52% of patients attained
their LDL-C treatment goal, as defined by the
NCEP ATP III 2004 updated guidelines. The
results reported here of the Egyptian arm of the
CEPHEUS study show that management of
hypercholesterolemia in Egypt is
comparatively worse than the average for
other similar countries in the region. Results
of other arms of the CEPHEUS study commonly
report that hypercholesterolemia is successfully
treated in only approximately 50% of cases
(Table 7). The individual results for the
proportion of patients achieving their NCEP
ATP III 2004 updated guideline-defined
treatment goal are: 52% for South Africa, 49%
for Greece, 57% for combined western
European countries and 49% for combined
Asian countries [18–21]. These results are in
contrast to other regions of the world, where
studies have reported that the majority of
patients actively treated for
hypercholesterolemia achieve their treatment
goals. For example, in Hong Kong, 83% of the
participants in the CEPHEUS study achieved
their treatment goal, and the Lipid treatment
assessment project 2 (L-TAP2) study, conducted
in nine countries in Europe, North America and
Asia, found the attainment rate was 73% in
these countries [22, 23]. Similarly, concerning
findings were also reported for the INTERHEART
study, conducted between 1999 and 2003,
which found that less than 5% of patients
admitted for their first AMI in the Middle East
were taking any lipid-lowering medications
(primary prevention), and this only increased
to 50% upon discharge (secondary prevention)
[3].
This study was an observational rather than
interventional study, and as such it suffers from
a number of limitations. There are likely to be
differences in clinical practice between study
sites, and this was not accounted for in the
combined analysis of the data. Furthermore, the
study population comprised only those patients
being actively treated with lipid-lowering
medication, and the proportion of eligible
patients with risk factors for CVD being
actively treated was not ascertained. In
addition, data on lifestyle factors or
socioeconomic status were not collected and,
therefore, not considered in the analysis. These
combined factors should be taken into
consideration when evaluating the findings.
At the time of conducting the study
(2010–2011), most physicians treated patients
according to the NCEP ATP III 2004 updated
guidelines. Since the end of the study, updated
guidance from the American College of
Cardiology and American Heart Association
has concluded that there was insufficient
evidence to support the continued use of LDL-
C or non-HDL-C treatment targets, instead
recommending different intensities of statin
treatment for patients based on four statin
benefit groups [24]. While it would be
interesting to apply the updated guidance to
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the results of this study, due to the enrolment
criterion of patients already receiving lipid-
lowering drugs for at least 3 months there are
no baseline measurements against which to
compare. Additionally, resource limitations
prevent us from re-classifying patients into the
revised risk groups to perform re-analyses
against the latest guidance, or from providing
additional statistical analyses on comparisons
between risk groups.
CONCLUSION
In conclusion, this study found that
hypercholesterolemia is not being effectively
managed in many at-risk patients in Egypt. The
majority of patients enrolled in the study, all of
whom were being actively treated with lipid-
lowering medication, were considered at high
risk of a cardiovascular event, and
hypercholesterolemia was particularly poorly
managed in this group. Initiatives to improve
physicians’ management of these patients and
patient compliance to treatment are urgently
needed.
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